These Highlights Do Not Include All The Information Needed To Use Ramelteon Tablets Safely And Effectively. See Full Prescribing Information For Ramelteon Tablets.

Carcinogenesis

Ramelteon was administered to mice and rats at oral doses of 0, 30, 100, 300, or 1000 mg/kg/day (mice) and 0, 15, 60, 250, or 1000 mg/kg/day (rats). Mice and rats were dosed for two years, except at the high dose (94 weeks for male and female mice and female rats). In mice, dose-related increases in the incidence of hepatic tumors (adenomas, carcinomas, hepatoblastomas) were observed in males and females. The no-effect dose for hepatic tumors in mice (30 mg/kg/day) is approximately 20 times the recommended human dose (RHD) of 8 mg/day based on body surface area (mg/m²).

In rats, the incidence of hepatic adenoma and benign Leydig cell tumors of the testis was increased in males at doses ≥250 mg/kg/day. In females, the incidence of hepatic adenoma was increased at doses ≥60 mg/kg/day. The incidence of hepatic carcinoma was increased in males and female rats at 1000 mg/kg/day. The no-effect dose for tumors in rats (15 mg/kg/day) is approximately 20 times the RHD based on mg/m².

Monitoring

No standard monitoring is required.

For patients presenting with unexplained amenorrhea, galactorrhea, decreased libido, or problems with fertility, assessment of prolactin levels and testosterone levels should be considered as appropriate.

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep container tightly closed and protected from moisture and humidity.

PRINCIPAL DISPLAY PANEL - 8 mg Bottle Label

NDC 70700-272-30

30 Tablets

Ramelteon tablets

8 mg

Each film-coated tablet contains 8 mg

of ramelteon.

Dispense with Medication Guide

in package insert or at

www.xiromed.com/medguides

Xiromed, LLC

Rx Only

PRINCIPAL DISPLAY PANEL - 8 mg Bottle Label

NDC 70700-272-10

100 Tablets

Ramelteon tablets

8 mg

Each film-coated tablet contains 8 mg

of ramelteon.

Dispense with Medication Guide

in package insert or at

www.xiromed.com/medguides

Xiromed, LLC

Rx Only

PRINCIPAL DISPLAY PANEL - 8 mg Bottle Label

NDC 70700-272-05

500 Tablets

Ramelteon tablets

8 mg

Each film-coated tablet contains 8 mg

of ramelteon.

Dispense with Medication Guide

in package insert or at

www.xiromed.com/medguides

Xiromed, LLC

Rx Only

General symptomatic and supportive measures should be used, along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. As in all cases of drug overdose, respiration, pulse, blood pressure, and other appropriate vital signs should be monitored, and general supportive measures employed.

Hemodialysis does not effectively reduce exposure to Ramelteon tablets. Therefore, the use of dialysis in the treatment of overdosage is not appropriate.

Ramelteon tablets are orally active hypnotic chemically designated as (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide and containing one chiral center. The compound is produced as the (S)-enantiomer, with an empirical formula of C₁₆H₂₁NO₂, molecular weight of 259.34, and the following chemical structure:

Ramelteon is freely soluble in organic solvents, such as methanol, ethanol, and dimethyl sulfoxide; soluble in 1-octanol and acetonitrile; and very slightly soluble in water and in aqueous buffers from pH 3 to pH 11.

Each Ramelteon tablet includes the following inactive ingredients: lactose monohydrate, corn starch, hydroxypropyl cellulose, magnesium stearate, opadry yellow and purified water.

Patients should avoid engaging in hazardous activities that require concentration (such as operating a motor vehicle or heavy machinery) after taking Ramelteon Tablets.

After taking Ramelteon Tablets, patients should confine their activities to those necessary to prepare for bed.

Patients should be advised not to consume alcohol in combination with Ramelteon Tablets as alcohol and Ramelteon Tablets may have additive effects when used in conjunction.

The effects of Ramelteon tablets were evaluated after administering a 16 mg dose or placebo in a crossover design to subjects (n=26) with mild to moderate obstructive sleep apnea. Treatment with Ramelteon tablets 16 mg for one night showed no difference compared with placebo on the Apnea/Hypopnea Index (the primary outcome variable), apnea index, hypopnea index, central apnea index, mixed apnea index, and obstructive apnea index. Treatment with a single dose of Ramelteon tablets does not exacerbate mild to moderate obstructive sleep apnea. There is no available information on the respiratory effects of multiple doses of Ramelteon tablets in patients with sleep apnea. The effects on exacerbation in patients with mild to moderate sleep apnea cannot be definitively known from this study.

Ramelteon tablets have not been studied in subjects with severe obstructive sleep apnea; use of Ramelteon tablets are not recommended in such patients.

Ramelteon tablets

Read the Medication Guide that comes with Ramelteon tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment.

What is the most important information I should know about Ramelteon tablets?

Ramelteon tablets may cause severe allergic reactions. Symptoms include swelling of the tongue or throat, trouble breathing, and nausea and vomiting. Get emergency medical help if you get these symptoms after taking Ramelteon tablets.

After taking Ramelteon tablets, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night. You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you sleepy with Ramelteon tablets. Activities may include:

• driving a car ("sleep-driving")
• making and eating food
• talking on the phone
• having sex
• sleep-walking

Call your doctor right away if you find out that you have done any of the above activities after taking Ramelteon tablets.

Important:

• 1.
  Take Ramelteon tablets exactly as prescribed
  • Do not take more Ramelteon tablets than prescribed.
  • Take Ramelteon tablets within 30 minutes of going to bed, not sooner.
• 2.
  Do not take Ramelteon tablets if you:
  • drink alcohol
  • take other medicines that can make you sleepy. Talk to your doctor about all of your medicines. Your doctor will tell you if you can take Ramelteon tablets with your other medicines
  • cannot get a full night's sleep

What are Ramelteon tablets?

Ramelteon tablets are hypnotic (sleep) medicine. Ramelteon tablets are used in adults for the treatment of the symptom of trouble falling asleep from insomnia.

Ramelteon tablets are not for children.

Who should not take Ramelteon tablets?

Do not take Ramelteon tablets if you are allergic to anything in it. See the end of this Medication Guide for a complete list of ingredients in Ramelteon tablets.

Do not take Ramelteon tablets if you are currently taking Luvox (fluvoxamine).

Ramelteon tablets may not be right for you. Before starting Ramelteon tablets, tell your doctor about all of your health conditions, including if you:

• have a history of depression, mental illness, or suicidal thoughts
• have liver disease
• have a lung disease or breathing problems
• are pregnant, or planning to become pregnant
• are breastfeeding or plan to breastfeed. Ramelteon tablets may cause somnolence in a breastfed infant. You may consider interrupting breastfeeding and pumping and discarding breastmilk during treatment and for 25 hours after administration of Ramelteon tablets.

Tell your doctor about all of the medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. Medicines can interact with each other, sometimes causing serious side effects.

Do not take Ramelteon tablets with:

• other medicines that can make you sleepy
• Luvox (fluvoxamine)

Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.

How should I take Ramelteon tablets?

• Take Ramelteon tablets exactly as prescribed. Do not take more Ramelteon tablets than prescribed for you.
• Do not break the tablets. They should be swallowed whole.
• Take Ramelteon tablets within 30 minutes of going to bed. After taking Ramelteon tablets only do activities to get ready for bed.
• Do not take Ramelteon tablets with or right after a meal.
• Do not take Ramelteon tablets unless you are able to get a full night's sleep before you must be active again.
• Call your doctor if your insomnia worsens or is not better within 7 to 10 days. This may mean that there is another condition causing your sleep problems.
• If you take too much Ramelteon tablets or overdose, call your doctor or poison control center right away, or get emergency treatment.

What are the possible side effects of Ramelteon tablets?

Possible serious side effects of Ramelteon tablets include:

• severe allergic reactions. Symptoms include swelling of the tongue or throat, trouble breathing, and nausea and vomiting. Get emergency medical help if you get these symptoms after taking Ramelteon tablets.
• getting out of bed while not being fully awake and do an activity that you do not know you are doing. (See "What is the most important information I should know about Ramellteon tablets?")
• abnormal thoughts and behavior. Symptoms include worsening of depression, suicidal thoughts or actions, nightmares, and hallucinations.
• hormone effects. Ramelteon tablets can decrease testosterone levels and increase prolactin levels in the blood. Symptoms of low testosterone or high prolactin levels are:
  • decreased interest in sex
  • problems getting pregnant
  • irregular menstrual periods or no menstrual periods
  • leakage of milk from the nipples of a person who is not breastfeeding

Call your doctor right away if you have any of the above side effects or any other side effects that worry you while using Ramelteon tablets. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

The most common side effects of Ramelteon tablets are:

• drowsiness
• tiredness
• dizziness
• You may still feel drowsy the next day after taking Ramelteon tablets. Do not drive or do other dangerous activities after taking Ramelteon tablets until you feel fully awake.

These are not all the side effects of Ramelteon tablets. Ask your doctor or pharmacist for more information.

How should I Store Ramelteon tablets?

• Store Ramelteon tablets at room temperature, 59° to 86° F (15° to 30°C). Keep the container tightly closed and protected from moisture and humidity.
• Keep Ramelteon tablets and all medicines out of reach of children.

General Information about Ramelteon tablets

• Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.
• Do not use Ramelteon tablets for a condition for which it was not prescribed.
• Do not share Ramelteon tablets with other people, even if you think they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about Ramelteon tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Ramelteon tablets that is written for healthcare professionals. For more information about Ramelteon tablets, please call Xiromed, LLC at 1-844-XIROMED (1-877-947-6633) or visit www.xiromed.com.

What are the ingredients in Ramelteon tablets?

Active Ingredient: ramelteon

Each Ramelteon tablet includes the following inactive ingredients: lactose monohydrate, corn starch, hydroxypropyl cellulose, magnesium stearate, opadry yellow and purified water.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Manufactured for:

Xiromed, LLC.

Florham Park, NJ 07932

Made in USA (30 count and 100 count)

Made in India (500 count)

PI-272-02   July 2023

Safety and effectiveness of Ramelteon tablets in pediatric patients have not been established. Further study is needed prior to determining that this product may be used safely in prepubescent and pubescent patients.

A total of 654 subjects in double-blind, placebo-controlled, efficacy trials who received Ramelteon tablets were at least 65 years of age; of these, 199 were 75 years of age or older. No overall differences in safety or efficacy were observed between elderly and younger adult subjects.

A double-blind, randomized, placebo-controlled study in elderly subjects with insomnia (n=33) evaluated the effect of a single dose of Ramelteon tablets on balance, mobility, and memory functions after middle of the night awakening. There is no information on the effect of multiple dosing. Night time dosing of Ramelteon tablets 8 mg did not impair middle of the night balance, mobility, or memory functions relative to placebo. The effects on night balance in the elderly cannot be definitively known from this study.

Patients who develop angioedema after treatment with Ramelteon Tablets should not be rechallenged with the drug.

Patients should not take Ramelteon Tablets in conjunction with fluvoxamine [see Drug Interactions (7)].

The following serious adverse reactions are discussed in greater detail in other sections:

• Severe anaphylactic and anaphylactoid reactions [see Warnings and Precautions (5.1)]
• Abnormal thinking, behavior changes, and complex behaviors [see Warnings and Precautions (5.3)]
• CNS effects [see Warnings and Precautions (5.4)]

• Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (7.1)
• Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (7.1)
• Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (7.1)
• Donepezil: Increases systemic exposure of ramelteon; patients should be closely monitored when ramelteon is coadministered with donepezil. (7.1)
• Doxepin: Increases systemic exposure of ramelteon; patients should be closely monitored when ramelteon is coadministered with doxepin. (7.1)
• Alcohol: Causes additive psychomotor impairment; should not be used in combination. (7.2)

The recommended dose of Ramelteon tablet is 8 mg taken within 30 minutes of going to bed. It is recommended that Ramelteon Tablets not be taken with or immediately after a high-fat meal.

The total Ramelteon Tablets dose should not exceed 8 mg per day.

No effects on C_max and AUC_0-t of parent drug or M-II were seen. No adjustment of Ramelteon tablet dosage is required in patients with renal impairment [see Clinical Pharmacology (12.4)].

The pharmacokinetic profile of Ramelteon tablets have been evaluated in healthy subjects as well as in subjects with hepatic or renal impairment. When administered orally to humans in doses ranging from 4 to 64 mg, ramelteon undergoes rapid, high first-pass metabolism, and exhibits linear pharmacokinetics. Maximal serum concentration (C_max) and area under the concentration-time curve (AUC) data show substantial intersubject variability, consistent with the high first-pass effect; the coefficient of variation for these values is approximately 100%. Several metabolites have been identified in human serum and urine.

Exposure to Ramelteon tablets was increased by four-fold in subjects with mild hepatic impairment and by more than ten-fold in subjects with moderate hepatic impairment. Ramelteon tablets should be used with caution in patients with moderate hepatic impairment [see Clinical Pharmacology (12.4)]. Ramelteon tablets are not recommended in patients with severe hepatic impairment.

Ramelteon Tablets are indicated for the treatment of insomnia characterized by difficulty with sleep onset.

The clinical trials performed in support of efficacy were up to six months in duration. The final formal assessments of sleep latency were performed after two days of treatment during the crossover study (elderly only), at five weeks in the six week studies (adults and elderly), and at the end of the six month study (adults and elderly) [see Clinical Studies (14)].

Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT₁ and MT₂ receptors and relative selectivity over the MT₃ receptor.

The activity of ramelteon at the MT₁ and MT₂ receptors is believed to contribute to its sleep-promoting properties, as these receptors, acted upon by endogenous melatonin, are thought to be involved in the maintenance of the circadian rhythm underlying the normal sleep-wake cycle.

Ramelteon has no appreciable affinity for the GABA receptor complex or for receptors that bind neuropeptides, cytokines, serotonin, dopamine, noradrenaline, acetylcholine, and opiates. Ramelteon also does not interfere with the activity of a number of selected enzymes in a standard panel.

The major metabolite of ramelteon, M-II, is pharmacologically active and has approximately one tenth and one fifth the binding affinity of the parent molecule for the human MT₁ and MT₂ receptors, respectively. However, M-II circulates at higher concentrations than the parent producing 20- to 100-fold greater mean systemic exposure when compared to ramelteon. Similar to ramelteon, M-II does not interfere with the activity of a number of endogenous enzymes.

All other known metabolites of ramelteon are inactive.

Ramelteon Tablets have been associated with an effect on reproductive hormones in adults, e.g., decreased testosterone levels and increased prolactin levels. It is not known what effect chronic or even chronic intermittent use of Ramelteon Tablets may have on the reproductive axis in developing humans [see Clinical Trials (14.3)].

• Severe anaphylactic/anaphylactoid reactions: Angioedema and anaphylaxis have been reported. Do not rechallenge if such reactions occur. (5.1)
• Need to evaluate for comorbid diagnoses: Reevaluate if insomnia persists after 7 to 10 days of treatment. (5.2)
• Abnormal thinking, behavioral changes, complex behaviors: May include "sleep-driving" and hallucinations. Immediately evaluate any new onset behavioral changes. (5.3)
• Depression: Worsening of depression or suicidal thinking may occur. (5.3)
• CNS effects: Potential impairment of activities requiring complete mental alertness such as operating machinery or driving a motor vehicle, after ingesting the drug. (5.4)
• Reproductive effects: Include decreased testosterone and increased prolactin levels. Effect on reproductive axis in developing humans is unknown. (5.5)
• Patients with severe sleep apnea: Ramelteon Tablets are not recommended for use in this population. (5.6)

Ramelteon tablets have a highly variable intersubject pharmacokinetic profile (approximately 100% coefficient of variation in C_max and AUC). As noted above, CYP1A2 is the major isozyme involved in the metabolism of Ramelteon tablets; the CYP2C subfamily and CYP3A4 isozymes are also involved to a minor degree.

• Adult dose: 8 mg taken within 30 minutes of going to bed. (2.1)
• Should not be taken with or immediately after a high-fat meal. (2.1)
• Total daily dose should not exceed 8 mg. (2.1)

Ramelteon tablets are not controlled substances.

Discontinuation of ramelteon in animals or in humans after chronic administration did not produce withdrawal signs. Ramelteon does not appear to produce physical dependence.

Ramelteon Tablets are available in an 8 mg strength tablet for oral administration.

Ramelteon Tablets 8 mg tablets are round, pale orange-yellow, film-coated tablets debossed with 'C' on one side and plain on other side.

• Pediatric use: Safety and effectiveness not established. (8.4)
• Geriatric use: No overall differences in safety and efficacy between elderly and younger adult subjects. (8.5)
• Hepatic impairment: Is not recommended in patients with severe impairment; use with caution in moderate impairment. (8.8)

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Ramelteon tablets, 8 mg are available as round, pale orange-yellow, biconvex film-coated tablets debossed with 'C' on one side and plain on the other side, in the following quantities:

Ramelteon Tablets are not known to interfere with commonly used clinical laboratory tests. In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro.

Ramelteon Tablets should not be used in combination with fluvoxamine. Ramelteon Tablets should be used with caution in patients taking other CYP1A2 inhibiting drugs [see Drug Interactions (7), Clinical Pharmacology (12.5)].

The respiratory depressant effect of Ramelteon tablets were evaluated in a crossover design study of subjects (n=26) with mild to moderate COPD after administering a single 16 mg dose or placebo, and in a separate study (n=25), the effects of Ramelteon tablets on respiratory parameters were evaluated after administering an 8 mg dose or placebo in a crossover design to patients with moderate to severe COPD, defined as patients who had forced expiratory volume at one second (FEV₁)/forced vital capacity ratio of <70%, and a FEV₁ <80% of predicted with <12% reversibility to albuterol. Treatment with a single dose of Ramelteon tablets have no demonstrable respiratory depressant effects in subjects with mild to severe COPD, as measured by arterial O2 saturation (SaO2). There is no available information on the respiratory effects of multiple doses of Ramelteon tablets in patients with COPD. The respiratory depressant effects in patients with COPD cannot be definitively known from this study.

Alcohol by itself impairs performance and can cause sleepiness. Since the intended effect of Ramelteon Tablets is to promote sleep, patients should be cautioned not to consume alcohol when using Ramelteon Tablets [see Clinical Pharmacology (12.5)]. Use of the products in combination may have an additive effect.

Since sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Worsening of insomnia, or the emergence of new cognitive or behavioral abnormalities, may be the result of an unrecognized underlying psychiatric or physical disorder and requires further evaluation of the patient. Exacerbation of insomnia and emergence of cognitive and behavioral abnormalities were seen with Ramelteon Tablets during the clinical development program.

Age

In a group of 24 elderly subjects aged 63 to 79 years administered a single Ramelteon tablets 16 mg dose, the mean C_max and AUC_0-inf values were 11.6 ng/mL (SD, 13.8) and 18.7 ng∙hr/mL (SD, 19.4), respectively. The elimination half-life was 2.6 hours (SD, 1.1). Compared with younger adults, the total exposure (AUC_0-inf) and C_max of ramelteon were 97 and 86% higher, respectively, in elderly subjects. The AUC_0-inf and C_max of M-II were increased by 30 and 13%, respectively, in elderly subjects.

Gender

There are no clinically meaningful gender-related differences in the pharmacokinetics of Ramelteon tablets or its metabolites.

Hepatic Impairment

Exposure to Ramelteon tablets were increased almost four-fold in subjects with mild hepatic impairment after seven days of dosing with 16 mg/day; exposure was further increased (more than ten-fold) in subjects with moderate hepatic impairment. Exposure to M-II was only marginally increased in mildly and moderately impaired subjects relative to healthy matched controls. The pharmacokinetics of Ramelteon tablets have not been evaluated in subjects with severe hepatic impairment (Child-Pugh Class C). Ramelteon tablets should be used with caution in patients with moderate hepatic impairment [see Warnings and Precautions (5.6)].

Renal Impairment

The pharmacokinetic characteristics of Ramelteon tablets were studied after administering a 16 mg dose to subjects with mild, moderate, or severe renal impairment based on predose creatinine clearance (53 to 95, 35 to 49, or 15 to 30 mL/min/1.73 m², respectively), and in subjects who required chronic hemodialysis. Wide intersubject variability were seen in Ramelteon tablets exposure parameters. However, no effects on C_max or AUC_0-t of parent drug or M-II were seen in any of the treatment groups; the incidence of adverse events was similar across groups. These results are consistent with the negligible renal clearance of ramelteon, which is principally eliminated via hepatic metabolism. No adjustment of Ramelteon tablets dosage is required in patients with renal impairment, including patients with severe renal impairment (creatinine clearance of ≤30 mL/min/1.73 m²) and patients who require chronic hemodialysis.

A variety of cognitive and behavior changes have been reported to occur in association with the use of hypnotics. In primarily depressed patients, worsening of depression (including suicidal ideation and completed suicides) has been reported in association with the use of hypnotics.

Hallucinations, as well as behavioral changes such as bizarre behavior, agitation and mania have been reported with Ramelteon Tablets use. Amnesia, anxiety and other neuro-psychiatric symptoms may also occur unpredictably.

Complex behaviors such as "sleep-driving" (i.e., driving while not fully awake after ingestion of a hypnotic) and other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex), with amnesia for the event, have been reported in association with hypnotic use. The use of alcohol and other CNS depressants may increase the risk of such behaviors. These events can occur in hypnotic-naive as well as in hypnotic-experienced persons. Complex behaviors have been reported with the use of Ramelteon Tablets. Discontinuation of Ramelteon Tablets should be strongly considered for patients who report any complex sleep behavior.

Ramelteon Tablets have not been studied in subjects with severe sleep apnea and is not recommended for use in this population [see Use in Specific Populations (8.7)].

Ramelteon Tablets should not be used by patients with severe hepatic impairment [see Clinical Pharmacology (12.4)].

Ramelteon Tablets are not recommended in patients with severe hepatic impairment. Ramelteon Tablets should be used with caution in patients with moderate hepatic impairment [see Warnings and Precautions (5.6), Clinical Pharmacology (12.4)].

Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of Ramelteon Tablets. Some patients have had additional symptoms such as dyspnea, throat closing, or nausea and vomiting that suggest anaphylaxis. Some patients have required medical therapy in the emergency department. If angioedema involves the tongue, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop angioedema after treatment with Ramelteon Tablets should not be rechallenged with the drug.

Two controlled studies evaluated the effects of Ramelteon tablets on endocrine function.

In the first trial, Ramelteon tablets 16 mg once daily or placebo was administered to 99 healthy volunteer subjects for four weeks. This study evaluated the thyroid axis, adrenal axis and reproductive axis. No clinically significant endocrinopathies were demonstrated in this study. However, the study was limited in its ability to detect such abnormalities due to its limited duration.

In the second trial, Ramelteon tablets 16 mg once daily or placebo was administered to 122 subjects with chronic insomnia for six months. This study evaluated the thyroid axis, adrenal axis and reproductive axis. There were no significant abnormalities seen in either the thyroid or the adrenal axes. Abnormalities were, however, noted within the reproductive axis. Overall, the mean serum prolactin level change from baseline was 4.9 mcg/L (34% increase) for women in the Ramelteon tablets group compared with -0.6 mcg/L (4% decrease) for women in the placebo group (p=0.003). No differences between active- and placebo-treated groups occurred among men. Thirty two percent of all patients who were treated with ramelteon in this study (women and men) had prolactin levels that increased from normal baseline levels compared to 19% of patients who were treated with placebo. Subject-reported menstrual patterns were similar between the two treatment groups.

In a 12 month, open-label study in adult and elderly patients, there were two patients who were noted to have abnormal morning cortisol levels, and subsequent abnormal ACTH stimulation tests. A 29 year old female patient was diagnosed with a prolactinoma. The relationship of these events to Ramelteon tablets therapy is not clear.

Carcinogenesis

Ramelteon was administered to mice and rats at oral doses of 0, 30, 100, 300, or 1000 mg/kg/day (mice) and 0, 15, 60, 250, or 1000 mg/kg/day (rats). Mice and rats were dosed for two years, except at the high dose (94 weeks for male and female mice and female rats). In mice, dose-related increases in the incidence of hepatic tumors (adenomas, carcinomas, hepatoblastomas) were observed in males and females. The no-effect dose for hepatic tumors in mice (30 mg/kg/day) is approximately 20 times the recommended human dose (RHD) of 8 mg/day based on body surface area (mg/m²).

In rats, the incidence of hepatic adenoma and benign Leydig cell tumors of the testis was increased in males at doses ≥250 mg/kg/day. In females, the incidence of hepatic adenoma was increased at doses ≥60 mg/kg/day. The incidence of hepatic carcinoma was increased in males and female rats at 1000 mg/kg/day. The no-effect dose for tumors in rats (15 mg/kg/day) is approximately 20 times the RHD based on mg/m².

Monitoring

No standard monitoring is required.

For patients presenting with unexplained amenorrhea, galactorrhea, decreased libido, or problems with fertility, assessment of prolactin levels and testosterone levels should be considered as appropriate.

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep container tightly closed and protected from moisture and humidity.

PRINCIPAL DISPLAY PANEL - 8 mg Bottle Label

NDC 70700-272-30

30 Tablets

Ramelteon tablets

8 mg

Each film-coated tablet contains 8 mg

of ramelteon.

Dispense with Medication Guide

in package insert or at

www.xiromed.com/medguides

Xiromed, LLC

Rx Only

PRINCIPAL DISPLAY PANEL - 8 mg Bottle Label

NDC 70700-272-10

100 Tablets

Ramelteon tablets

8 mg

Each film-coated tablet contains 8 mg

of ramelteon.

Dispense with Medication Guide

in package insert or at

www.xiromed.com/medguides

Xiromed, LLC

Rx Only

PRINCIPAL DISPLAY PANEL - 8 mg Bottle Label

NDC 70700-272-05

500 Tablets

Ramelteon tablets

8 mg

Each film-coated tablet contains 8 mg

of ramelteon.

Dispense with Medication Guide

in package insert or at

www.xiromed.com/medguides

Xiromed, LLC

Rx Only

General symptomatic and supportive measures should be used, along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. As in all cases of drug overdose, respiration, pulse, blood pressure, and other appropriate vital signs should be monitored, and general supportive measures employed.

Hemodialysis does not effectively reduce exposure to Ramelteon tablets. Therefore, the use of dialysis in the treatment of overdosage is not appropriate.

Ramelteon tablets are orally active hypnotic chemically designated as (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide and containing one chiral center. The compound is produced as the (S)-enantiomer, with an empirical formula of C₁₆H₂₁NO₂, molecular weight of 259.34, and the following chemical structure:

Ramelteon is freely soluble in organic solvents, such as methanol, ethanol, and dimethyl sulfoxide; soluble in 1-octanol and acetonitrile; and very slightly soluble in water and in aqueous buffers from pH 3 to pH 11.

Each Ramelteon tablet includes the following inactive ingredients: lactose monohydrate, corn starch, hydroxypropyl cellulose, magnesium stearate, opadry yellow and purified water.

Patients should avoid engaging in hazardous activities that require concentration (such as operating a motor vehicle or heavy machinery) after taking Ramelteon Tablets.

After taking Ramelteon Tablets, patients should confine their activities to those necessary to prepare for bed.

Patients should be advised not to consume alcohol in combination with Ramelteon Tablets as alcohol and Ramelteon Tablets may have additive effects when used in conjunction.

The effects of Ramelteon tablets were evaluated after administering a 16 mg dose or placebo in a crossover design to subjects (n=26) with mild to moderate obstructive sleep apnea. Treatment with Ramelteon tablets 16 mg for one night showed no difference compared with placebo on the Apnea/Hypopnea Index (the primary outcome variable), apnea index, hypopnea index, central apnea index, mixed apnea index, and obstructive apnea index. Treatment with a single dose of Ramelteon tablets does not exacerbate mild to moderate obstructive sleep apnea. There is no available information on the respiratory effects of multiple doses of Ramelteon tablets in patients with sleep apnea. The effects on exacerbation in patients with mild to moderate sleep apnea cannot be definitively known from this study.

Ramelteon tablets have not been studied in subjects with severe obstructive sleep apnea; use of Ramelteon tablets are not recommended in such patients.

Ramelteon tablets

Read the Medication Guide that comes with Ramelteon tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment.

What is the most important information I should know about Ramelteon tablets?

Ramelteon tablets may cause severe allergic reactions. Symptoms include swelling of the tongue or throat, trouble breathing, and nausea and vomiting. Get emergency medical help if you get these symptoms after taking Ramelteon tablets.

After taking Ramelteon tablets, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night. You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you sleepy with Ramelteon tablets. Activities may include:

• driving a car ("sleep-driving")
• making and eating food
• talking on the phone
• having sex
• sleep-walking

Call your doctor right away if you find out that you have done any of the above activities after taking Ramelteon tablets.

Important:

• 1.
  Take Ramelteon tablets exactly as prescribed
  • Do not take more Ramelteon tablets than prescribed.
  • Take Ramelteon tablets within 30 minutes of going to bed, not sooner.
• 2.
  Do not take Ramelteon tablets if you:
  • drink alcohol
  • take other medicines that can make you sleepy. Talk to your doctor about all of your medicines. Your doctor will tell you if you can take Ramelteon tablets with your other medicines
  • cannot get a full night's sleep

What are Ramelteon tablets?

Ramelteon tablets are hypnotic (sleep) medicine. Ramelteon tablets are used in adults for the treatment of the symptom of trouble falling asleep from insomnia.

Ramelteon tablets are not for children.

Who should not take Ramelteon tablets?

Do not take Ramelteon tablets if you are allergic to anything in it. See the end of this Medication Guide for a complete list of ingredients in Ramelteon tablets.

Do not take Ramelteon tablets if you are currently taking Luvox (fluvoxamine).

Ramelteon tablets may not be right for you. Before starting Ramelteon tablets, tell your doctor about all of your health conditions, including if you:

• have a history of depression, mental illness, or suicidal thoughts
• have liver disease
• have a lung disease or breathing problems
• are pregnant, or planning to become pregnant
• are breastfeeding or plan to breastfeed. Ramelteon tablets may cause somnolence in a breastfed infant. You may consider interrupting breastfeeding and pumping and discarding breastmilk during treatment and for 25 hours after administration of Ramelteon tablets.

Tell your doctor about all of the medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. Medicines can interact with each other, sometimes causing serious side effects.

Do not take Ramelteon tablets with:

• other medicines that can make you sleepy
• Luvox (fluvoxamine)

Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.

How should I take Ramelteon tablets?

• Take Ramelteon tablets exactly as prescribed. Do not take more Ramelteon tablets than prescribed for you.
• Do not break the tablets. They should be swallowed whole.
• Take Ramelteon tablets within 30 minutes of going to bed. After taking Ramelteon tablets only do activities to get ready for bed.
• Do not take Ramelteon tablets with or right after a meal.
• Do not take Ramelteon tablets unless you are able to get a full night's sleep before you must be active again.
• Call your doctor if your insomnia worsens or is not better within 7 to 10 days. This may mean that there is another condition causing your sleep problems.
• If you take too much Ramelteon tablets or overdose, call your doctor or poison control center right away, or get emergency treatment.

What are the possible side effects of Ramelteon tablets?

Possible serious side effects of Ramelteon tablets include:

• severe allergic reactions. Symptoms include swelling of the tongue or throat, trouble breathing, and nausea and vomiting. Get emergency medical help if you get these symptoms after taking Ramelteon tablets.
• getting out of bed while not being fully awake and do an activity that you do not know you are doing. (See "What is the most important information I should know about Ramellteon tablets?")
• abnormal thoughts and behavior. Symptoms include worsening of depression, suicidal thoughts or actions, nightmares, and hallucinations.
• hormone effects. Ramelteon tablets can decrease testosterone levels and increase prolactin levels in the blood. Symptoms of low testosterone or high prolactin levels are:
  • decreased interest in sex
  • problems getting pregnant
  • irregular menstrual periods or no menstrual periods
  • leakage of milk from the nipples of a person who is not breastfeeding

Call your doctor right away if you have any of the above side effects or any other side effects that worry you while using Ramelteon tablets. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

The most common side effects of Ramelteon tablets are:

• drowsiness
• tiredness
• dizziness
• You may still feel drowsy the next day after taking Ramelteon tablets. Do not drive or do other dangerous activities after taking Ramelteon tablets until you feel fully awake.

These are not all the side effects of Ramelteon tablets. Ask your doctor or pharmacist for more information.

How should I Store Ramelteon tablets?

• Store Ramelteon tablets at room temperature, 59° to 86° F (15° to 30°C). Keep the container tightly closed and protected from moisture and humidity.
• Keep Ramelteon tablets and all medicines out of reach of children.

General Information about Ramelteon tablets

• Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.
• Do not use Ramelteon tablets for a condition for which it was not prescribed.
• Do not share Ramelteon tablets with other people, even if you think they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about Ramelteon tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Ramelteon tablets that is written for healthcare professionals. For more information about Ramelteon tablets, please call Xiromed, LLC at 1-844-XIROMED (1-877-947-6633) or visit www.xiromed.com.

What are the ingredients in Ramelteon tablets?

Active Ingredient: ramelteon

Each Ramelteon tablet includes the following inactive ingredients: lactose monohydrate, corn starch, hydroxypropyl cellulose, magnesium stearate, opadry yellow and purified water.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Manufactured for:

Xiromed, LLC.

Florham Park, NJ 07932

Made in USA (30 count and 100 count)

Made in India (500 count)

PI-272-02   July 2023

Safety and effectiveness of Ramelteon tablets in pediatric patients have not been established. Further study is needed prior to determining that this product may be used safely in prepubescent and pubescent patients.

A total of 654 subjects in double-blind, placebo-controlled, efficacy trials who received Ramelteon tablets were at least 65 years of age; of these, 199 were 75 years of age or older. No overall differences in safety or efficacy were observed between elderly and younger adult subjects.

A double-blind, randomized, placebo-controlled study in elderly subjects with insomnia (n=33) evaluated the effect of a single dose of Ramelteon tablets on balance, mobility, and memory functions after middle of the night awakening. There is no information on the effect of multiple dosing. Night time dosing of Ramelteon tablets 8 mg did not impair middle of the night balance, mobility, or memory functions relative to placebo. The effects on night balance in the elderly cannot be definitively known from this study.

Patients who develop angioedema after treatment with Ramelteon Tablets should not be rechallenged with the drug.

Patients should not take Ramelteon Tablets in conjunction with fluvoxamine [see Drug Interactions (7)].

The following serious adverse reactions are discussed in greater detail in other sections:

• Severe anaphylactic and anaphylactoid reactions [see Warnings and Precautions (5.1)]
• Abnormal thinking, behavior changes, and complex behaviors [see Warnings and Precautions (5.3)]
• CNS effects [see Warnings and Precautions (5.4)]

• Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (7.1)
• Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (7.1)
• Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (7.1)
• Donepezil: Increases systemic exposure of ramelteon; patients should be closely monitored when ramelteon is coadministered with donepezil. (7.1)
• Doxepin: Increases systemic exposure of ramelteon; patients should be closely monitored when ramelteon is coadministered with doxepin. (7.1)
• Alcohol: Causes additive psychomotor impairment; should not be used in combination. (7.2)

The recommended dose of Ramelteon tablet is 8 mg taken within 30 minutes of going to bed. It is recommended that Ramelteon Tablets not be taken with or immediately after a high-fat meal.

The total Ramelteon Tablets dose should not exceed 8 mg per day.

No effects on C_max and AUC_0-t of parent drug or M-II were seen. No adjustment of Ramelteon tablet dosage is required in patients with renal impairment [see Clinical Pharmacology (12.4)].

The pharmacokinetic profile of Ramelteon tablets have been evaluated in healthy subjects as well as in subjects with hepatic or renal impairment. When administered orally to humans in doses ranging from 4 to 64 mg, ramelteon undergoes rapid, high first-pass metabolism, and exhibits linear pharmacokinetics. Maximal serum concentration (C_max) and area under the concentration-time curve (AUC) data show substantial intersubject variability, consistent with the high first-pass effect; the coefficient of variation for these values is approximately 100%. Several metabolites have been identified in human serum and urine.

Exposure to Ramelteon tablets was increased by four-fold in subjects with mild hepatic impairment and by more than ten-fold in subjects with moderate hepatic impairment. Ramelteon tablets should be used with caution in patients with moderate hepatic impairment [see Clinical Pharmacology (12.4)]. Ramelteon tablets are not recommended in patients with severe hepatic impairment.

Ramelteon Tablets are indicated for the treatment of insomnia characterized by difficulty with sleep onset.

The clinical trials performed in support of efficacy were up to six months in duration. The final formal assessments of sleep latency were performed after two days of treatment during the crossover study (elderly only), at five weeks in the six week studies (adults and elderly), and at the end of the six month study (adults and elderly) [see Clinical Studies (14)].

Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT₁ and MT₂ receptors and relative selectivity over the MT₃ receptor.

The activity of ramelteon at the MT₁ and MT₂ receptors is believed to contribute to its sleep-promoting properties, as these receptors, acted upon by endogenous melatonin, are thought to be involved in the maintenance of the circadian rhythm underlying the normal sleep-wake cycle.

Ramelteon has no appreciable affinity for the GABA receptor complex or for receptors that bind neuropeptides, cytokines, serotonin, dopamine, noradrenaline, acetylcholine, and opiates. Ramelteon also does not interfere with the activity of a number of selected enzymes in a standard panel.

The major metabolite of ramelteon, M-II, is pharmacologically active and has approximately one tenth and one fifth the binding affinity of the parent molecule for the human MT₁ and MT₂ receptors, respectively. However, M-II circulates at higher concentrations than the parent producing 20- to 100-fold greater mean systemic exposure when compared to ramelteon. Similar to ramelteon, M-II does not interfere with the activity of a number of endogenous enzymes.

All other known metabolites of ramelteon are inactive.

Ramelteon Tablets have been associated with an effect on reproductive hormones in adults, e.g., decreased testosterone levels and increased prolactin levels. It is not known what effect chronic or even chronic intermittent use of Ramelteon Tablets may have on the reproductive axis in developing humans [see Clinical Trials (14.3)].

• Severe anaphylactic/anaphylactoid reactions: Angioedema and anaphylaxis have been reported. Do not rechallenge if such reactions occur. (5.1)
• Need to evaluate for comorbid diagnoses: Reevaluate if insomnia persists after 7 to 10 days of treatment. (5.2)
• Abnormal thinking, behavioral changes, complex behaviors: May include "sleep-driving" and hallucinations. Immediately evaluate any new onset behavioral changes. (5.3)
• Depression: Worsening of depression or suicidal thinking may occur. (5.3)
• CNS effects: Potential impairment of activities requiring complete mental alertness such as operating machinery or driving a motor vehicle, after ingesting the drug. (5.4)
• Reproductive effects: Include decreased testosterone and increased prolactin levels. Effect on reproductive axis in developing humans is unknown. (5.5)
• Patients with severe sleep apnea: Ramelteon Tablets are not recommended for use in this population. (5.6)

Ramelteon tablets have a highly variable intersubject pharmacokinetic profile (approximately 100% coefficient of variation in C_max and AUC). As noted above, CYP1A2 is the major isozyme involved in the metabolism of Ramelteon tablets; the CYP2C subfamily and CYP3A4 isozymes are also involved to a minor degree.

• Adult dose: 8 mg taken within 30 minutes of going to bed. (2.1)
• Should not be taken with or immediately after a high-fat meal. (2.1)
• Total daily dose should not exceed 8 mg. (2.1)

Ramelteon tablets are not controlled substances.

Discontinuation of ramelteon in animals or in humans after chronic administration did not produce withdrawal signs. Ramelteon does not appear to produce physical dependence.

Ramelteon Tablets are available in an 8 mg strength tablet for oral administration.

Ramelteon Tablets 8 mg tablets are round, pale orange-yellow, film-coated tablets debossed with 'C' on one side and plain on other side.

• Pediatric use: Safety and effectiveness not established. (8.4)
• Geriatric use: No overall differences in safety and efficacy between elderly and younger adult subjects. (8.5)
• Hepatic impairment: Is not recommended in patients with severe impairment; use with caution in moderate impairment. (8.8)

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Ramelteon tablets, 8 mg are available as round, pale orange-yellow, biconvex film-coated tablets debossed with 'C' on one side and plain on the other side, in the following quantities:

Ramelteon Tablets are not known to interfere with commonly used clinical laboratory tests. In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro.

Ramelteon Tablets should not be used in combination with fluvoxamine. Ramelteon Tablets should be used with caution in patients taking other CYP1A2 inhibiting drugs [see Drug Interactions (7), Clinical Pharmacology (12.5)].

The respiratory depressant effect of Ramelteon tablets were evaluated in a crossover design study of subjects (n=26) with mild to moderate COPD after administering a single 16 mg dose or placebo, and in a separate study (n=25), the effects of Ramelteon tablets on respiratory parameters were evaluated after administering an 8 mg dose or placebo in a crossover design to patients with moderate to severe COPD, defined as patients who had forced expiratory volume at one second (FEV₁)/forced vital capacity ratio of <70%, and a FEV₁ <80% of predicted with <12% reversibility to albuterol. Treatment with a single dose of Ramelteon tablets have no demonstrable respiratory depressant effects in subjects with mild to severe COPD, as measured by arterial O2 saturation (SaO2). There is no available information on the respiratory effects of multiple doses of Ramelteon tablets in patients with COPD. The respiratory depressant effects in patients with COPD cannot be definitively known from this study.

Alcohol by itself impairs performance and can cause sleepiness. Since the intended effect of Ramelteon Tablets is to promote sleep, patients should be cautioned not to consume alcohol when using Ramelteon Tablets [see Clinical Pharmacology (12.5)]. Use of the products in combination may have an additive effect.

Since sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Worsening of insomnia, or the emergence of new cognitive or behavioral abnormalities, may be the result of an unrecognized underlying psychiatric or physical disorder and requires further evaluation of the patient. Exacerbation of insomnia and emergence of cognitive and behavioral abnormalities were seen with Ramelteon Tablets during the clinical development program.

Age

In a group of 24 elderly subjects aged 63 to 79 years administered a single Ramelteon tablets 16 mg dose, the mean C_max and AUC_0-inf values were 11.6 ng/mL (SD, 13.8) and 18.7 ng∙hr/mL (SD, 19.4), respectively. The elimination half-life was 2.6 hours (SD, 1.1). Compared with younger adults, the total exposure (AUC_0-inf) and C_max of ramelteon were 97 and 86% higher, respectively, in elderly subjects. The AUC_0-inf and C_max of M-II were increased by 30 and 13%, respectively, in elderly subjects.

Gender

There are no clinically meaningful gender-related differences in the pharmacokinetics of Ramelteon tablets or its metabolites.

Hepatic Impairment

Exposure to Ramelteon tablets were increased almost four-fold in subjects with mild hepatic impairment after seven days of dosing with 16 mg/day; exposure was further increased (more than ten-fold) in subjects with moderate hepatic impairment. Exposure to M-II was only marginally increased in mildly and moderately impaired subjects relative to healthy matched controls. The pharmacokinetics of Ramelteon tablets have not been evaluated in subjects with severe hepatic impairment (Child-Pugh Class C). Ramelteon tablets should be used with caution in patients with moderate hepatic impairment [see Warnings and Precautions (5.6)].

Renal Impairment

The pharmacokinetic characteristics of Ramelteon tablets were studied after administering a 16 mg dose to subjects with mild, moderate, or severe renal impairment based on predose creatinine clearance (53 to 95, 35 to 49, or 15 to 30 mL/min/1.73 m², respectively), and in subjects who required chronic hemodialysis. Wide intersubject variability were seen in Ramelteon tablets exposure parameters. However, no effects on C_max or AUC_0-t of parent drug or M-II were seen in any of the treatment groups; the incidence of adverse events was similar across groups. These results are consistent with the negligible renal clearance of ramelteon, which is principally eliminated via hepatic metabolism. No adjustment of Ramelteon tablets dosage is required in patients with renal impairment, including patients with severe renal impairment (creatinine clearance of ≤30 mL/min/1.73 m²) and patients who require chronic hemodialysis.

A variety of cognitive and behavior changes have been reported to occur in association with the use of hypnotics. In primarily depressed patients, worsening of depression (including suicidal ideation and completed suicides) has been reported in association with the use of hypnotics.

Hallucinations, as well as behavioral changes such as bizarre behavior, agitation and mania have been reported with Ramelteon Tablets use. Amnesia, anxiety and other neuro-psychiatric symptoms may also occur unpredictably.

Complex behaviors such as "sleep-driving" (i.e., driving while not fully awake after ingestion of a hypnotic) and other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex), with amnesia for the event, have been reported in association with hypnotic use. The use of alcohol and other CNS depressants may increase the risk of such behaviors. These events can occur in hypnotic-naive as well as in hypnotic-experienced persons. Complex behaviors have been reported with the use of Ramelteon Tablets. Discontinuation of Ramelteon Tablets should be strongly considered for patients who report any complex sleep behavior.

Ramelteon Tablets have not been studied in subjects with severe sleep apnea and is not recommended for use in this population [see Use in Specific Populations (8.7)].

Ramelteon Tablets should not be used by patients with severe hepatic impairment [see Clinical Pharmacology (12.4)].

Ramelteon Tablets are not recommended in patients with severe hepatic impairment. Ramelteon Tablets should be used with caution in patients with moderate hepatic impairment [see Warnings and Precautions (5.6), Clinical Pharmacology (12.4)].

Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of Ramelteon Tablets. Some patients have had additional symptoms such as dyspnea, throat closing, or nausea and vomiting that suggest anaphylaxis. Some patients have required medical therapy in the emergency department. If angioedema involves the tongue, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop angioedema after treatment with Ramelteon Tablets should not be rechallenged with the drug.

Two controlled studies evaluated the effects of Ramelteon tablets on endocrine function.

In the first trial, Ramelteon tablets 16 mg once daily or placebo was administered to 99 healthy volunteer subjects for four weeks. This study evaluated the thyroid axis, adrenal axis and reproductive axis. No clinically significant endocrinopathies were demonstrated in this study. However, the study was limited in its ability to detect such abnormalities due to its limited duration.

In the second trial, Ramelteon tablets 16 mg once daily or placebo was administered to 122 subjects with chronic insomnia for six months. This study evaluated the thyroid axis, adrenal axis and reproductive axis. There were no significant abnormalities seen in either the thyroid or the adrenal axes. Abnormalities were, however, noted within the reproductive axis. Overall, the mean serum prolactin level change from baseline was 4.9 mcg/L (34% increase) for women in the Ramelteon tablets group compared with -0.6 mcg/L (4% decrease) for women in the placebo group (p=0.003). No differences between active- and placebo-treated groups occurred among men. Thirty two percent of all patients who were treated with ramelteon in this study (women and men) had prolactin levels that increased from normal baseline levels compared to 19% of patients who were treated with placebo. Subject-reported menstrual patterns were similar between the two treatment groups.

In a 12 month, open-label study in adult and elderly patients, there were two patients who were noted to have abnormal morning cortisol levels, and subsequent abnormal ACTH stimulation tests. A 29 year old female patient was diagnosed with a prolactinoma. The relationship of these events to Ramelteon tablets therapy is not clear.